Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Cancer driver mutations affecting the histone H3.3 chromatin remodellers ATRX and DAXX were recently discovered in 43% of sporadic pancreatic neuroendocrine tumours (PNET). Progressive age-dependent replacement of canonical H3.1/2 with H3.3 is crucial for maintaining genome integrity through expression of repressive markers at heterochromatic sites, where loading is mediated by ATRX and DAXX. Loss of H3.3 chaperones in PNET is associated with activation of ALT, a telomere maintenance mechanism, eventually leading to chromosome instability. It has been suggested that ATRX/DAXX expression is necessary for repressing ALT, but mechanistic details of this interaction are not fully understood.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Sposito T
Authors: Sposito T, C Nguyen Tu M, Thirlwell C, Salomoni P,
Keywords: PNET, mouse model, epigenetic,
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,
Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,
Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Lepage C
Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,
Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,
Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Raderer M
Authors: Raderer M, Hörsch D, Lahner H, Rinke A, Denecke T,
Keywords: GEP-NET, Lanreotide, Temozolomide,
Introduction: PRRT using Lu-177 is a treatment option for advanced NETs.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Mc Ewan A, Wieler M, Makis W, McMullen T, Morrish D,
Keywords: neuroendocrine, Lu-177-DOTA-TATE,